標(biāo)題: Titlebook: Liquid Biopsy in Cancer Patients; The Hand Lens for Tu Antonio Russo,Antonio Giordano,Christian Rolfo Book 2017 Springer International Publ [打印本頁] 作者: 斷巖 時(shí)間: 2025-3-21 18:32
書目名稱Liquid Biopsy in Cancer Patients影響因子(影響力)
書目名稱Liquid Biopsy in Cancer Patients影響因子(影響力)學(xué)科排名
書目名稱Liquid Biopsy in Cancer Patients網(wǎng)絡(luò)公開度
書目名稱Liquid Biopsy in Cancer Patients網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Liquid Biopsy in Cancer Patients被引頻次
書目名稱Liquid Biopsy in Cancer Patients被引頻次學(xué)科排名
書目名稱Liquid Biopsy in Cancer Patients年度引用
書目名稱Liquid Biopsy in Cancer Patients年度引用學(xué)科排名
書目名稱Liquid Biopsy in Cancer Patients讀者反饋
書目名稱Liquid Biopsy in Cancer Patients讀者反饋學(xué)科排名
作者: 慟哭 時(shí)間: 2025-3-21 23:19 作者: 不舒服 時(shí)間: 2025-3-22 03:16 作者: 遷移 時(shí)間: 2025-3-22 07:57
Walter Arancio,Beatrice Belmonte,Marta Castiglia,Arianna Di Napoli,Claudio Tripodo: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio978-3-540-78644-3Series ISSN 1615-1844 Series E-ISSN 1616-9522 作者: Irremediable 時(shí)間: 2025-3-22 11:50 作者: abnegate 時(shí)間: 2025-3-22 12:56
Simona Fontana,Marco Giallombardo,Riccardo Alessandro: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio978-3-540-78644-3Series ISSN 1615-1844 Series E-ISSN 1616-9522 作者: Fresco 時(shí)間: 2025-3-22 18:23
Lorena Incorvaia,Marta Castiglia,Alessandro Perez,Daniela Massihnia,Stefano Caruso MD, PhD,Sevilay A: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio978-3-540-78644-3Series ISSN 1615-1844 Series E-ISSN 1616-9522 作者: 破譯 時(shí)間: 2025-3-22 23:29
M. Castiglia,A. Listì,L. Incorvaia,V. Chiantera,Antonio Russo: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio978-3-540-78644-3Series ISSN 1615-1844 Series E-ISSN 1616-9522 作者: Instinctive 時(shí)間: 2025-3-23 01:53 作者: CULP 時(shí)間: 2025-3-23 07:07 作者: 低位的人或事 時(shí)間: 2025-3-23 12:09 作者: modish 時(shí)間: 2025-3-23 17:34
Daniele Fanale,Lorena Incorvaia,Marta Castiglia,Nadia Barraco,Giuseppe Badalamenti,Alex Le Cesne,Ant: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio978-3-540-78644-3Series ISSN 1615-1844 Series E-ISSN 1616-9522 作者: motivate 時(shí)間: 2025-3-23 20:28
Estíbaliz Alegre,Leyre Zubiri,Juan Pablo Fusco,Natalia Ramírez,álvaro González,Ignacio Gil-Bazo: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio978-3-540-78644-3Series ISSN 1615-1844 Series E-ISSN 1616-9522 作者: 輕率的你 時(shí)間: 2025-3-23 22:50 作者: BRAND 時(shí)間: 2025-3-24 05:01
A. Russo,A. Giordano,C. Rolfoave been subjected to critical evaluation, like in these volumes. Critical evaluation means: there where contradictory information is published data and conclusions are being analyzed, broken down to the firm facts and - interpreted in the light of all present knowledge. Depending on the information作者: 裂隙 時(shí)間: 2025-3-24 10:03 作者: circumvent 時(shí)間: 2025-3-24 13:29
Pierluigi Scalia MD, PhD,Stephen J. Williams,Antonio Russo,Antonio Giordanove been subjected to critical evaluation, like in these volumes. Critical evaluation means: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio作者: 有雜色 時(shí)間: 2025-3-24 16:48
A. Galvano,K. Papadimitriou,B. Di Stefano,M. Castiglia,Christian Rolfo MD, PhDve been subjected to critical evaluation, like in these volumes. Critical evaluation means: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio作者: hazard 時(shí)間: 2025-3-24 19:51
Ismail Labgaa MD,Amanda J. Craig BS,Augusto Villanueva MD, PhDve been subjected to critical evaluation, like in these volumes. Critical evaluation means: there where contradictory information is published data and conc lusions are being analyzed, broken down to the firm facts and re interpreted in the light of all present knowledge. Depending on the informatio作者: BOGUS 時(shí)間: 2025-3-24 23:53 作者: ANNUL 時(shí)間: 2025-3-25 03:29 作者: 神圣在玷污 時(shí)間: 2025-3-25 10:25
Cancer Clonal Evolution and Intra-tumor Heterogeneity,romotes and drives a genetic selection mechanism of fittest cell clones. Usually, the origin of tumor heterogeneity may be explained by two theoretical models potentially complementary, the clonal evolution model and cancer stem cell (CSC) hypothesis. The intra-tumor heterogeneity detected in most o作者: ABHOR 時(shí)間: 2025-3-25 11:46
Actionable Molecular Targets in Cancer Liquid Biopsy,technologies as well as in pathway-driven biology knowledge of the cancer process now allow medical science to adopt universal pre-analytical and analytic methodologies. The key aspect that currently concerns the medical oncology field still remains what molecular targets should be pursued in the cl作者: Bother 時(shí)間: 2025-3-25 18:14 作者: Tartar 時(shí)間: 2025-3-25 21:05
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC),s back, new advances and discoveries make them, together with the ctDNA, a very promising tool. In the following chapter we will discuss the recent advances of liquid biopsy in NSCLC highlighting the possible clinical utility of CTCs, ctDNA and exosomes.作者: 潰爛 時(shí)間: 2025-3-26 00:22
Liquid Biopsy in Esophageal, Gastric, and Pancreatic Cancers, pancreatic cancers for a better desease management. In this chapter we will discuss how CTCs, exosomes and circulating nucleic acids can be used to obtain prognostic and predictive information and also could be a useful tool for early diagnosis.作者: aesthetic 時(shí)間: 2025-3-26 08:19 作者: FLACK 時(shí)間: 2025-3-26 10:54
Liquid Biopsies in Malignant Melanoma: From Bench to Bedside,ecting the right treatment for the proper patient..In this new scenario, serological tumour markers should be reviewed. Among them, potential circulating biomarkers such as cell-free DNA, exosomes, microRNA and circulating tumour cells have been identified..In this chapter, we will summarize classic作者: miscreant 時(shí)間: 2025-3-26 12:43 作者: conformity 時(shí)間: 2025-3-26 18:54
Clinical Practice Implications: Monitoring Drug Response and Resistance, involve solid tissues but the extraction of blood or other body fluids [3]. Liquid biopsy cannot completely replace the tissue biopsies, but it may offer a valid alternative for patients with advanced disease who have no tissue availability or to refine the oncological decision-making process [1–3]作者: transient-pain 時(shí)間: 2025-3-26 23:13
2197-781X in Cancer Patients: The Hand Lens for Tumor Evolution.?is targeted to resident and fellows physicians, medical oncologists, molecular biologists and biotechnologists..978-3-319-85719-0978-3-319-55661-1Series ISSN 2197-781X Series E-ISSN 2197-7828 作者: 殘忍 時(shí)間: 2025-3-27 01:31 作者: CHOP 時(shí)間: 2025-3-27 06:58 作者: expeditious 時(shí)間: 2025-3-27 11:34 作者: 尖酸一點(diǎn) 時(shí)間: 2025-3-27 14:56 作者: 一再困擾 時(shí)間: 2025-3-27 19:58
978-3-319-85719-0Springer International Publishing AG 2017作者: 極小量 時(shí)間: 2025-3-28 00:20 作者: 清晰 時(shí)間: 2025-3-28 02:20 作者: 輕而薄 時(shí)間: 2025-3-28 07:34
Precision Oncology: Present Status and Perspectives,ofiling approaches and by the integrative genomics, which is now shifting the interest from single-gene to multilayer molecular analysis, are described. Precision oncology will be a major challenge but have the potential to provide changing practice opportunities for cancer treatment in the next years.作者: MAUVE 時(shí)間: 2025-3-28 11:39 作者: CHASE 時(shí)間: 2025-3-28 18:11
Tissue Versus Liquid Biopsy: Opposite or Complementary?,of the tissue (i.e., dysplasia) are funding elements in the diagnosis of malignancies, yet the pieces of information conveyed by these features are often insufficient for the precise identification of a specific cancer histotype, and sometimes they prove faulty [1–6].作者: Camouflage 時(shí)間: 2025-3-28 21:27
Liquid Biopsy in Gynecological Cancers,ent-resistance in gynecological cancer patients. The ability to detect circulating tumor DNA (ct-DNA), Exosome and Circulating miRNA, as novel molecular biomarkers is possible thanks to the advent of novel high throughput sequencing technologies and new analytical techniques, which favoured the spreading of the personalized medicine worldwide.作者: 羅盤 時(shí)間: 2025-3-29 00:21 作者: menopause 時(shí)間: 2025-3-29 04:18
Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctst sources for CNAs due to the very simple and minimally invasive way of sampling. Moreover, it can be repeated at different time points, giving the opportunity for a real-time monitoring of the disease.作者: Pamphlet 時(shí)間: 2025-3-29 09:00
Technical Aspects for the Evaluation of Exosomes and Their Content,tic application. This chapter focuses on the isolation and study of exosomes from liquid biopsies and summarizes the recent exosomal miRNA and protein profiling data supporting the potential role of tumor-derived exosomes as biomarkers and their potential application in clinical settings.作者: Pageant 時(shí)間: 2025-3-29 14:44 作者: Felicitous 時(shí)間: 2025-3-29 17:11
2197-781X nding field of “l(fā)iquid biopsy” for the management of cancer This text is designed to provide readers with a useful and comprehensive resource and state-of-the-art overview about the new, growing and fast-expanding field of “l(fā)iquid biopsy” for the management of cancer patients. The liquid biopsy repr作者: Conclave 時(shí)間: 2025-3-29 20:03
Book 2017ing field of “l(fā)iquid biopsy” for the management of cancer patients. The liquid biopsy represents an important turning point in oncology since it provides a tool for a serial monitoring of disease. Liquid biopsy is our “hand lens” to follow molecular changes that characterize tumor development and pr作者: 遭受 時(shí)間: 2025-3-30 02:10
Liquid Biopsy in Cancer Patients: The Hand Lens to Investigate Tumor Evolution,elopment and progression. Several tumors are defined as “oncogene addicted” and this discovery has led the way to the development of target therapies that are able to specifically kill cancer cells sparing normal cells from toxicity. Nowadays treatment decision is strictly dependent on the molecular作者: Thyroid-Gland 時(shí)間: 2025-3-30 06:03 作者: 上腭 時(shí)間: 2025-3-30 09:03
Cancer Clonal Evolution and Intra-tumor Heterogeneity, to different therapies represents the main obstacle to the successful treatment, resulting in poor prognosis and tumor recurrence. Currently, understanding the causes underlying this resistance is the main objective of oncology research in recent years. Tumors are not uniform diseases but heterogen作者: essential-fats 時(shí)間: 2025-3-30 16:16 作者: indecipherable 時(shí)間: 2025-3-30 17:48 作者: LIMN 時(shí)間: 2025-3-30 21:04 作者: 迅速飛過 時(shí)間: 2025-3-31 03:38
Technical Aspects for the Evaluation of Exosomes and Their Content,, strongly depending on the nature of the transported molecules (proteins, mRNAs, miRNAs, and lipids)..Since a significant body of literature has demonstrated that exosomes released by cancer cells carry tumor-specific RNAs and proteins, they are widely considered very attractive targets for diagnos作者: 饒舌的人 時(shí)間: 2025-3-31 07:55 作者: Ingredient 時(shí)間: 2025-3-31 09:52
Liquid Biopsy in Breast Cancer,on individual’s risk of relapse, the patients undergo adjuvant systemic treatment to decrease the risk of recurrence. Current BC classification and assessment remain strongly based on clinicopathological criteria, including patient age, tumor size, lymph node invasion, histological type, and grade. 作者: 昏暗 時(shí)間: 2025-3-31 16:37 作者: Hla461 時(shí)間: 2025-3-31 21:16 作者: Malleable 時(shí)間: 2025-3-31 23:18
